leukemia Archives | Oncotarget

Oncotarget News

Oncotarget

DDX41 and Its Unique Contribution to Myeloid Leukemogenesis

July 19, 2024

myeloid neoplasms associated with DDX41 variants likely exhibit a unique pathogenesis that diverges from the conventional understanding of myeloid neoplasms.”BUFFALO, NY- July 19, 2024 – A new editorial paper was... read more

Oncotarget

Editorial: Genomics Has More to Reveal

July 2, 2024

If there was any doubt, this discovery demonstrates that genomics, extensively deployed over the past two decades, still has much to reveal to us.”BUFFALO, NY- July 2, 2024 – A... read more

Oncotarget

BTK Inhibitor-related Cardiotoxicity: The Quest for Predictive Biomarkers and Improved Risk Stratification

June 4, 2024

due to the general lack of robust predictive biomarkers, a standardized risk stratification tool is not utilized in clinical practice – a prime area for research.”BUFFALO, NY- June 4, 2024 –... read more

Figure 2: Effect of treatment with MIA-602 on the growth of Doxorubicin-resistant K-562 tumors xenographed into nude mice.

Oncotarget

Exploring the Role of MIA-602 in Overcoming Doxorubicin-resistance in Acute Myeloid Leukemia

April 10, 2024

Our results reveal that MIA-602 may be a useful treatment for Doxorubicin-resistant AML [...]”BUFFALO, NY- April 10, 2024 – A new research paper was published in Oncotarget's Volume 15 on April... read more

Figure 6: Effects of various drug combinations on molecular markers of apoptosis in patient-derived cell samples.

Oncotarget

ABT199/Venetoclax Synergism With Thiotepa in Acute Myeloid Leukemia (AML) Cells

March 25, 2024

the combination of ABT199/venetoclax and Thio enhances the cytotoxicity of (Flu+Clad+Bu) in AML cell lines and leukemia patient-derived cell samples.”BUFFALO, NY- March 25, 2024 – A new... read more

Oncotarget

C/EBPβ Cooperates With MYB to Maintain the Oncogenic Program of AML Cells

November 13, 2023

This makes C/EBPβ an interesting pro-oncogenic player in AML, worthy of further studies.”BUFFALO, NY- November 13, 2023 – A new editorial perspective was published in Oncotarget's Volume 14 on... read more

Figure 1: Graphical illustration of the main findings from Pfeiffer et al., Cancer Research, 2022. Combined Inhibition of SHP2 and Mutated RTKs Prevent Acquired Resistance in Leukemia

Oncotarget

Combined Inhibition of SHP2 and Mutated RTKs Prevent Acquired Resistance in Leukemia

November 8, 2023

In summary, this study reveals a molecular escape mechanism of mutated RTK-driven leukemic cells from SHP2 allosteric inhibition [...]”BUFFALO, NY- November 8, 2023 – A new editorial paper was published in... read more

Figure 1: Scheme of mechanisms of AGO2 (de)regulation and its (novel) functions in T-PLL.

Oncotarget

AGO2 in T-prolymphocytic Leukemia (T-PLL)

August 7, 2023

For the first time, descriptive and mechanistic data implicated the involvement of molecules of the RNA interference (RNAi) machinery in T-PLL’s leukemogenesis [...]” BUFFALO, NY- August 7, 2023 – A... read more

Figure 1: Mechanisms of MCL-1 inhibitor-induced MCL-1 protein upregulation, stability, and induction of apoptosis.

Oncotarget

Decoding the Mechanism Behind MCL-1 Inhibitors: A Pathway to Understanding MCL-1 Protein Stability

June 28, 2023

Taken together, the study provides novel insights into the regulation of MCL-1 expression by MCL1i, associated molecular changes and their implications.”BUFFALO, NY- June 28, 2023 – A new editorial paper... read more

Figure 2: Polyclonal, Clonal and Restricted Repertoire Phenotypes in Clonality Testing.

Oncotarget

Automated, Accurate Reporting for NGS-Based Clonality Testing

May 16, 2023

we have developed a fully automated calling algorithm for determining B and T cell clonality from NGS [next-generation sequencing] data, with greater sensitivity than previously developed models.”BUFFALO, NY- May... read more